News
-
-
-
COMMUNIQUÉ DE PRESSE
STEMMER IMAGING AG: MiddleGround Capital concludes investment agreement with STEMMER IMAGING and announces voluntary public takeover offer at EUR 48.00 per share
MiddleGround Capital concludes investment agreement with STEMMER IMAGING and announces voluntary public takeover offer at EUR 48.00 per share. Expected completion in Q4 2024 -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: STEMMER IMAGING AG: MiddleGround Capital concludes investment agreement with STEMMER IMAGING and announces voluntary public takeover offer at EUR 48.00 per share
MiddleGround Capital announces voluntary public takeover offer for STEMMER IMAGING AG at EUR 48.00 per share to support long-term growth. Offer premium at 52% to closing price on July 19, 2024 -
-
COMMUNIQUÉ DE PRESSE
HOPIUM franchit avec succès le cap des tests sur banc d'essai - Des performances supérieures aux attentes pour la pile Hopium de 100 kW
Hopium franchit avec succès le cap des tests sur banc d'essai, les performances de sa pile de 100 kW surpassent les attentes. Développement de technologies de pointe pour décarboner les transports lourds -
COMMUNIQUÉ DE PRESSE
EQS-WpÜG: Takeover Offer / Target company: STEMMER IMAGING AG; Bidder: Blitz 24-884 AG (in future: Ventrifossa BidCo AG)
Blitz 24-884 AG (future name: Ventrifossa BidCo AG) announces a voluntary public takeover offer for STEMMER IMAGING AG. Offer includes a premium of approx. 41% to the share price. Bidder has secured majority shares -
COMMUNIQUÉ DE PRESSE
Press release: Blue Elephant Energy commissions its first self-developed project in Germany
Blue Elephant Energy commissions its first self-developed 7.6 MWp solar park in Germany, partnering with greentech systems GmbH and Deutsche Kreditbank AG. The project marks the kick-off for BEE's global development pipeline -
-
COMMUNIQUÉ DE PRESSE
Biophytis déploie sa stratégie de partenariats et signe deux contrats avec des agents locaux en Asie
Biophytis déploie sa stratégie de partenariats en Asie en signant deux contrats avec des agents locaux. Objectif : accélérer le déploiement du candidat-médicament BIO101 dans la région
